Risk and outcome in metastatic malignant melanoma patients receiving DTIC, cisplatin, BCNU and tamoxifen followed by immunotherapy with interleukin 2 and interferon alpha2a.

Combined chemo-/immunotherapy has shown high objective response rates and a significant though small proportion of long-term complete responders in metastatic malignant melanoma. The purpose of this study was to determine response rates, freedom from treatment failure (FFTF) and overall survival in...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Hoffmann, R., Müller, I., Neuber, K., Lassmann, S., Buer, J., Probst, M., Oevermann, K., Franzke, A., Kirchner, H., Ganser, A., Atzpodien, J.
Formato: Artigo
Lenguaje:Inglês
Publicado: Nature Publishing Group|1 1998
Materias:
Research Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC2063152/
https://ncbi.nlm.nih.gov/pubmed/9792153
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares